Curve Therapeutics Secures $40.5M for Innovative Biotech Advancements
Curve Therapeutics, a biotechnology company based in Southampton, UK, recently secured $40.5M in Series A funding. The funding round was led by Pfizer Ventures, with additional investment from Columbus Venture Partners, British Patient Capital, Advent Life Sciences, and Epidarex Capital. With this injection of capital, the company aims to advance the development of its portfolio of assets towards clinical trials and expand its innovative discovery platform to target even more challenging intracellular protein targets.
Under the leadership of CEO Simon Kerry, Curve Therapeutics specializes in using its revolutionary Microcycle® platform to identify novel therapeutics that can effectively address complex and hard-to-treat diseases.
The company's platform has the capability to directly discover biologically active molecules that can target disease mechanisms that have previously been resistant to traditional drug discovery techniques. Some of the promising assets in Curve's pipeline include a groundbreaking dual-inhibitor of HIF-1 and HIF-2, which has the potential to disrupt survival mechanisms in a wide range of solid tumors, as well as an innovative ATIC dimerization inhibitor that targets a critical vulnerability in multiple types of cancer.
By securing significant financial backing and with a strong team of founders and investors on board, Curve Therapeutics is well-positioned to make meaningful advancements in the field of biotechnology. With a focus on developing transformative therapies that could significantly impact patient outcomes, the company is committed to pushing the boundaries of drug discovery and bringing innovative treatments to market. With its cutting-edge technology and a clear mission, Curve Therapeutics is poised to make a lasting impact on the healthcare industry.
They've invested in Curve Therapeutics
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Pfizer Ventures | 2 investment(s) investment(s) | 7 contacts contacts | |||
2 |  Columbus Venture Partners | 1 investment(s) investment(s) | 7 contacts contacts | |||
3 |  British Patient Capital | 8 investment(s) investment(s) | 25 contacts contacts | |||
4 |  Advent Life Sciences | 3 investment(s) investment(s) | 10 contacts contacts | |||
5 |  Epidarex Capital | 3 investment(s) investment(s) | more info |
Click here for a full list of 6,481+ startup investors in the UK